Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/48731
Title: Aligning kidney function assessment in patients with cancer to global practices in internal medicine
Authors: Sandhu, Geeta
Adattini, Josephine
Gordon, Evangeline Armstrong
O'neill, Niamh
Bagnis, Corrine
Chambers, Pinkie
Martin, Jennifer H.
Flynn, Alex
Ibrahim, Karim
Jardine, Meg J.
Johnson, David W.
Jones, Graham R. D.
Karapetis, Christos S.
Kelly, Aisling
Kichenadasse, Ganessan
Kliman, David S.
Liauw, Winston
Lucas, Catherine
Mallett, Andrew J.
Malyszko, Jolanta
Michael, Michael
Pollock, Carol A.
Roberts, Darren M.
Rosner, Mitchell H.
Routledge, David J. M.
Scuderi, Carla
Shingleton, Julia
Shortt, Jake
Siderov, Jim
SPRANGERS, Ben 
Stein, Brian N.
Tunnicliffe, David J.
Webber, Kate
Ward, Robyn L.
Issue Date: 2025
Publisher: ELSEVIER
Source: EClinicalMedicine, 82 (Art N° 103102)
Abstract: The kidney disease: Improving Global Outcomes (KDIGO) guideline recommends assessing kidney function using glomerular filtration rate (GFR) either through direct measurement or through estimation (eGFR) and describes a standardised classification of reduced kidney function. KDIGO guidelines have been adopted by most internal medicine specialities for the assessment and classification of kidney function, but not by cancer medicine. The development of the International Consensus Guideline on Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) aims to overcome the perceived challenges with KDIGO recommendations by describing their utility in patients with cancer. Two virtual, consensus building workshops were held consecutively, involving international, multidisciplinary participants (Part 1 of ADDIKD development). During these workshops, three consensus recommendations were agreed upon based on KDIGO's principles; to standardise kidney function assessment, classify kidney function, and determine a uniform approach to dose anticancer drugs in patients with reduced kidney mendations. These issues were addressed by nephrologists, clinical pharmacologists, and other clinicians with extensive experience in the contemporary assessment of kidney function. The key concern for cancer specialists was a hesitancy to move away from the familiar and long-standing practice of using the Cockcroft-Gault equation to estimate creatinine clearance. The consensus building within the two multidisciplinary workshops allowed a thorough assessment of the evidence and clarified how directly measured GFR and eGFR, rather than creatinine clearance, could be optimally utilised in cancer care. The development of Part 1 of the ADDIKD guideline represents a standardised, contemporary approach to the assessment, classification, and utility of kidney function in the setting of cancer care and it harmonises with the approach used in other areas of medicine internationally.
Notes: Sandhu, G (corresponding author), Univ Sydney, Fac Med & Hlth, Sydney, NSW, Australia.; Sandhu, G (corresponding author), Canc Inst NSW, EviQ, St Leonards, NSW, Australia.; Sandhu, G (corresponding author), St Vincents Hosp, Pharm Dept, Sydney, NSW, Australia.
geetpal.sandhu@svha.org.au
Keywords: Chemotherapy;Drug dosing;Kidney dysfunction;Renal;Oncology;Haematology;Pharmacokinetics
Document URI: http://hdl.handle.net/1942/48731
e-ISSN: 2589-5370
DOI: 10.1016/j.eclinm.2025.103102
ISI #: 001700957000001
Rights: 2025 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Category: A1
Type: Journal Contribution
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
main.pdfPublished version291.01 kBAdobe PDFView/Open
Show full item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.